5-Fluoro-2-Oxindole CAS 56341-41-4 Purity >99.0% (LCMS) Sunitinib Malate Intermediate Factory

Short Description:

Chemical Name: 5-Fluoro-2-Oxindole

CAS: 56341-41-4

Purity: >99.0% (LCMS)

Appearance: Light Yellow Crystalline Powder

Intermediate of Sunitinib Malate (CAS: 341031-54-7)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 5-Fluoro-2-Oxindole (CAS: 56341-41-4) with high quality, commercial production. Welcomed to order.

Chemical Properties:

Chemical Name	5-Fluoro-2-Oxindole
Synonyms	5-Fluorooxindole; 5-Fluoro-2-indolinone; 5-Fluoroindolin-2-one; 5-Fluoro-1,3-Dihydro-indol-2-one
CAS Number	56341-41-4
CAT Number	RF-PI1543
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C8H6FNO
Molecular Weight	151.14
Density	1.311±0.06 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Light Yellow Crystalline Powder
1 H NMR Spectrum	Consistent With Structure
LCMS	Consistent With Structure
Purity / Analysis Method	>99.0% (LCMS)
Melting Point	143.0~147.0℃
Loss on Drying	<0.50%
Total Impurities	<1.00%
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates; Sunitinib Malate Intermediate

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

5-Fluoro-2-Oxindole (CAS: 56341-41-4) is mainly used in pharmaceutical industry as a pharmaceutical intermediate. 5-Fluoro-2-Oxindole is an intermediate in the synthesis of Sunitinib Malate (CAS: 341031-54-7). Sunitinib Malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “Suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases.